



A 2025 VISION FOR CATALONIA

# Scaling-up the BioRegion of Catalonia

[informe.biocat.cat](http://informe.biocat.cat)  
[www.biocat.cat](http://www.biocat.cat)



@biocat\_cat

@biocat\_es

@biocat\_es

# CATALONIA / BARCELONA: A GROWING INNOVATION HUB IN EUROPE

INNOVATION IN CITIES AROUND THE WORLD, 2017  
Position of Barcelona




Source: 2thinknow, Innovation Cities Index




In the first semester of 2018,  
17 multinationals announced  
new innovation set-ups in  
Catalonia.


# KEY SECTOR PLAYERS AT A WALKING DISTANCE





# BARCELONA IS #34 IN SCIENCE OUTPUT WORLDWIDE (AND #8 IN EUROPE)




The top 500 cities by scientific output in 2017



# CATALONIA IS CURRENTLY ONE OF THE LEADING SCIENTIFIC HUBS IN EUROPE




## Descobriment de nous medicaments, dispositius mèdics o mètodes diagnòstics innovadors



**Quin serà el paper de Catalunya en innovació en salut?**

# FINANCE RAISED IS ON UPWARD TREND, ESPECIALLY REGARDING PRIVATE INVESTMENT (investment in startups, in €M)

**Investment that creates value**



# INTERNATIONAL INVESTORS ARE INCREASING


# 50


## International investors

(x10 in just 5 years)



# SUCCESS STORIES IN FUNDRAISING

	2015	2016	2017	2018
<b>€11-50 M Invested</b>	 	   	 	  
<b>€1-10 M Invested</b>	        	          	            	       



# FUNDS RAISED BY ICREA-CO-FUNDED BIOTECH COMPANIES

Company	M€
Minoryx Therapeutics	49,7
Mosaic Biomedicals	47
Abac Therapeutics	16
Aelix Therapeutics	13,2
Bionure Farma	7
Ability Pharma	6,64
Peptomyc	6,4
Inbiomotion	4,55
Leukos Biotech	3,84
SOM Biotech	3,8
Albajuna Therapeutics	3,75
Iproteos	3,18
ProteoDesign	3,07
Sagetus Biotech	2,35
Ahead Therapeutics	1,3
VCN Biosciences	1,1
Nanoligent	0,89
Senolytic Therapeutics	0,76
FreeOx Biotech	0,7
Cytes Biotechnologies	0,58



- **70% of finance raised by biotech startups ( $\leq 10$  years) are ICREA-co-founded**
- **There are 73 ICREA researchers and 6,500 CERCA researchers in life sciences**

# PERFORMANCE IN TERMS OF SPINOFFS


## TOP 15 RESEARCH BODIES AND FINANCE RAISED BY SPINOFF

- Universities create more spinoffs than any other entity, but those created by research centers are the most attractive for investors.

Research entities	Finance raised by spinoff companies (M€)
Vall d'Hebron (VHIR, VHIO)	54,5
Universitat de Barcelona (UB)*	54,4
Institut Químic de Sarrià (IQS)	34,8
Universitat Autònoma de Barcelona (UAB)	29,2
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)	21,3
Institut de Recerca de la Sida (Irsi-Caixa)	15,3
Hospital Clínic de Barcelona	14,6
Institut de Recerca Biomèdica de Barcelona (IRB Barcelona)	10,8
Institut de Biologia Molecular de Barcelona (IBMB)	9,4
Institut de Recerca Contra la Leucèmia Josep Carreras (IJC)	3,8
Universitat Pompeu Fabra (UPF)	3,8
Universitat Politècnica de Catalunya (UPC)	3,7
Universitat Rovira i Virgili (URV)	3
Hospital de Sant Joan de Déu (HSJD)	2,6
Universitat de Girona (UdG)	2,5

# MOVING CUTTING EDGE SCIENCE TOWARDS PATIENTS

**19 new therapies  
developed by  
new companies**



# THE LAST 2018 10 MONTHS IN THE BIOREGION

**FierceBiotech**

BIOTECH RESEARCH CRO MEDTECH

**Biotech**

## Roche-backed Minoryx raises €21M to expand CNS R&D

by Nick Paul Taylor | Sep 26, 2018 8:50am

Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.

Spain's Minoryx established itself as an emerging player in neurodegeneration R&D in 2015 when it raised a €19.4 million series A round to take PPAR-gamma agonist MIN-102 into clinical trials. Three years later, Minoryx has advanced MIN-102 into a phase 2/3 trial in patients with the inherited spinal cord condition adrenomyeloneuroopathy.



Jordi Carrera, un dels cofundadors de STAT-Dx juntament amb Rafael Bru. (GUÍASET)

### La 'start-up' biomèdica STAT-Dx, comprada per 152 milions

ALBERT MARTÍN

STAT-Dx una companyia poc coneguda amb seu a Barcelona i dedicada a la biotecnologia, es la protagonista de la que se serà una de les operacions de compra més rellevants de l'any. L'empresa ha arribat

naixement com a STAT-Diagnostic, està participada per Kurma Partners, Jahnvest Partners, Glide Healthcare, Boehringer Ingelheim Venture Fund, Caixa Capital Risc, Axis i Yios Capital. Precisament aquest últim

## Alta Life Sciences lidera una inversió de 3 milions a Mediktor

L'avaliador de síntomas inicia l'expansió als Estats Units

Marc García

Es calcula que set de cada deu persones han tingut almenys un moment, primer consideren els síntomes a Google. També hi ha un tracte d'emergència que no sempre és urgent. Posar la solució ideal per a aquest problema, i decidir si cal actuar o no, és el que pretén aquest primer contacte, el doctor Christian Pascual, fundador i director de la startup catalana que vol plantar a Crític (ingenier, va ser director a Roche) i que ha fet una inversió de 3 milions d'euros en la startup de Lleida.

Van ser els inversors els que el 2011 a construir la base de dades de la startup, que permet fer un inventari en forma d'aplicació mòbil gratuïta en aquells que han fet una consulta a Google i que

els que han consultat els dossiers



Els cofundadors de Mediktor Christian Pascual i Oscar García-Espíndola

**CISION** News Products Contact

News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest

## Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the "Clinical Trials on Alzheimer's Disease" (CTAD) congress on October 27, 2018 in Barcelona.

AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD

NEWS PROVIDED BY  
Grifols →  
Oct 27, 2018, 03:30 ET

promoció dels beneficis genètics a la Clínica de Prediacció i Prevenció en la seva etapa d'evolució, i en els nous projectes d'investigació en la Nació

## FierceBiotech

Gilead has teamed up with Aelix Therapeutics to trial a combination designed to free people with HIV from the need to take antiretroviral drugs. The planned clinical trial will test Gilead's TLR7 agonist in combination with Aelix's T-cell vaccine.

Gilead began testing the TLR7 agonist, vatasolimod, in HIV patients in 2016. In animal models, the combination of the drug and a broadly neutralizing antibody suppressed HIV for six months without additional treatment. The early-stage finding dialed up hopes that vatasolimod can boost immune responses and thereby contribute to the elimination of virus-infected cells.

Vatasolimod may need support to achieve HIV suppression, though. That's where Aelix comes in. The Spanish biotech is developing a T-cell vaccine designed to orchestrate immune attacks on vulnerable parts of HIV. Aelix's interest in the approach grew out of research into people who are

## Oryzon amplía capital para financiar proyectos de I+D

**CAPTA 13 MILLONES DE EUROS** / La biotecnológica catalana tiene en marcha cinco ensayos clínicos en fase IIa para sus moléculas 'ladaderstat y 'vafidermstat'.

GARIBÉ TORIBIO, Barcelona


Oryzon Genomics cerró ayer una ampliación de capital dirigida a inversores institucionales internacionales y españoles por 13 millones de euros. Los fondos levantados apoyan el crecimiento y balance de la compañía para continuar con el arsenal de proyectos de I+D que ha puesto en marcha en los últimos meses. "Estamos muy contentos de haber podido ampliar la operación, pese al viraje brusco de los mercados financieros en las últimas semanas", explica el presidente y fundador de la empresa, Carlos Buesa.

La biotecnológica, con sede operativa en Cornellà de Llobregat




El presidente de Oryzon Genomics, Carlos Buesa.

# LIFE SCIENCES VENTURE FINANCING (€M) BY COUNTRY (2000-2017)



# VISION 2025



## **KEY STRENGTHS**

---

- 1. EXCELLENT SCIENCE**
- 2. ENTREPRENEURIAL SPIRIT AND CREATIVITY**
- 3. PROFESSIONAL TALENT AND INNOVATIVE  
INDUSTRY**
- 4. LOCAL INVESTORS AND SMART MONEY**
- 5. REASONABLE ADMINISTRATION**
- 6. VALUES**

**Many hubs start-up...  
just a few scale-up**